Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Operating Expenses: 2013-2025

Historic Operating Expenses for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $55.9 million.

  • Coherus Oncology's Operating Expenses rose 5.66% to $55.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.4 million, marking a year-over-year increase of 11.11%. This contributed to the annual value of $378.6 million for FY2024, which is 17.77% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Operating Expenses is $55.9 million, which was up 0.29% from $55.7 million recorded in Q2 2025.
  • Coherus Oncology's Operating Expenses' 5-year high stood at $250.4 million during Q1 2021, with a 5-year trough of $49.9 million in Q2 2024.
  • Over the past 3 years, Coherus Oncology's median Operating Expenses value was $70.1 million (recorded in 2024), while the average stood at $91.2 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 232.48% in 2021, then plummeted by 50.36% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Operating Expenses stood at $112.9 million in 2021, then declined by 14.23% to $96.8 million in 2022, then skyrocketed by 65.66% to $160.4 million in 2023, then increased by 28.22% to $205.7 million in 2024, then grew by 5.66% to $55.9 million in 2025.
  • Its Operating Expenses was $55.9 million in Q3 2025, compared to $55.7 million in Q2 2025 and $53.0 million in Q1 2025.